Liraglutide is fabricated by adhering a C-16 blubbery acid (palmitic acid) with a glutamic acid spacer on the actual lysine balance at position 26 of the peptide precursor.
Liraglutide is a once-daily GLP-1 acquired for the analysis of blazon 2 diabetes. GLP-1, in its accustomed form, is brief in the physique (the half-life afterwards subcutaneous bang is about one hour), so it is not actual advantageous as a ameliorative agent. However, liraglutide has a half-life afterwards subcutaneous bang of 11–15 hours, authoritative it acceptable for once-daily dosing. The abiding activity of liraglutide is accomplished by adhering a blubbery acid atom at one position of the GLP-1 molecule, enabling it to bind to albumin aural the subcutaneous tissue and bloodstream. The alive GLP-1 is again appear from albumin at a slow, constant rate. Binding with albumin aswell after-effects in slower abasement and bargain abolishment of liraglutide from the apportionment by the kidneys compared to GLP-1.
Liraglutide is an acylated GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Liraglutide upregulates intracellular cAMP consistent in the absolution of insulin accustomed animated claret glucose concentrations. Glucagon beard is aswell decreased in a glucose-dependent appearance by liraglutide.